The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 925-931

  Ramos Espiritu, Lavoisier S ^a   Hess, Kenneth C ^a   Buck, Jochen ^a   Levin, Lonny R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC GMP; LIFICIGUAT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHODIESTERASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CYCLIC AMP; CYCLIC GMP; ENZYME ACTIVATORS; ENZYME INHIBITORS; GLUCOSE; GUANYLATE CYCLASE; INDAZOLES; INSULIN-SECRETING CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; OXADIAZOLES; OXAZINES; PHOSPHORIC DIESTER HYDROLASES; PYRIMIDINES; QUINOXALINES; RATS; TRANSCRIPTION, GENETIC;

EID: 80052173193     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184135     Document Type: Article

References (50)

1. Asfari M, Janjic D, Meda P, Li G, Halban PA, and Wollheim CB (1992) Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130:167-178.
2. Ashcroft FM and Rorsman P (1989) Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol 54:87-143.
3. Boswell-Smith V, Spina D, and Page CP (2006) Phosphodiesterase inhibitors. Br J Pharmacol 147:S252-S257. (Pubitemid 43077283)
4. Buck J, Sinclair ML, Schapal L, Cann MJ, and Levin LR (1999) Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals. Proc Natl Acad Sci USA 96:79-84. (Pubitemid 29036056)
5. Chaloupka JA, Bullock SA, Iourgenko V, Levin LR, and Buck J (2006) Autoinhibitory regulation of soluble adenylyl cyclase. Mol Reprod Dev 73:361-368. (Pubitemid 43262051)
6. Charles MA, Fanska R, Schmid FG, Forsham PH, and Grodsky GM (1973) Adenosine 3′,5′-monophosphate in pancreatic islets: glucose-induced insulin release. Science 179:569-571.
7. Chen Y, Cann MJ, Litvin TN, Iourgenko V, Sinclair ML, Levin LR, and Buck J (2000) Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science 289:625-628. (Pubitemid 30622067)
8. Chiang WC, Teng CM, Lin SL, Chen YM, Tsai TJ, and Hsieh BS (2005) YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Eur J Pharmacol 517:1-10.
9. Chien WL, Liang KC, and Fu WM (2008) Enhancement of active shuttle avoidance response by the NO-cGMP-PKG activator YC-1. Eur J Pharmacol 590:233-240.
10. Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, and Fu WM (2003) Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol Pharmacol 63:1322-1328.
11. Derbyshire ER, Fernhoff NB, Deng S, and Marletta MA (2009) Nucleotide regulation of soluble guanylate cyclase substrate specificity. Biochemistry 48:7519-7524.
12. Farrell J, Ramos L, Tresguerres M, Kamenetsky M, Levin LR, and Buck J (2008) Somatic 'soluble' adenylyl cyclase isoforms are unaffected in Sacy tm1Lex/Sacy tm1Lex 'knockout' mice. PLoS One 3:e3251.
13. Fisher DA, Smith JF, Pillar JS, St. Denis SH, and Cheng JB (1998) Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246:570-577. (Pubitemid 28420898)
14. Friebe A and Koesling D (1998) Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 53:123-127. (Pubitemid 28068379)
15. Friebe A, Russwurm M, Mergia E, and Koesling D (1999) A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site? Biochemistry 38:15253-15257.
16. Friebe A, Schultz G, and Koesling D (1996) Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 15:6863-6868. (Pubitemid 27023257)
17. Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C, and Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127:195-203. (Pubitemid 29213249)
18. Garthwaite G, Goodwin DA, Neale S, Riddall D, and Garthwaite J (2002) Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition. Mol Pharmacol 61:97-104. (Pubitemid 34049516)
19. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, and Mayer B (1995) Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48:184-188.
20. Geng W, Wang Z, Zhang J, Reed BY, Pak CY, and Moe OW (2005) Cloning and characterization of the human soluble adenylyl cyclase. Am J Physiol Cell Physiol 288:C1305-C1316. (Pubitemid 40991068)
21. Ghosh R, Sawant O, Ganpathy P, Pitre S, and Kadam VJ (2009) Phosphodiesterase inhibitors: their role and implications. Int J PharmTech Res 1:1148-1160.
22. Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, and Seifert R (2004) Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279:19955-19969. (Pubitemid 38623438)
23. Grill V and Cerasi E (1973) Activation by glucose of adenyl cyclase in pancreatic islets of the rat. FEBS Lett 33:311-314.
24. Hess KC, Jones BH, Marquez B, Chen Y, Ord TS, Kamenetsky M, Miyamoto C, Zippin JH, Kopf GS, Suarez SS, et al. (2005) The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization. Dev Cell 9:249-259. (Pubitemid 41051743)
25. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, and Beavo JA (2000) Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci USA 97:12891-12895.
26. Hwang TL, Hung HW, Kao SH, Teng CM, Wu CC, and Cheng SJ (2003) Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol Pharmacol 64:1419-1427.
27. Hwang TL, Zhuo SK, and Pan YL (2008) YC-1 attenuates homotypic human neutrophil aggregation through inhibition of phosphodiesterase activity. Eur J Pharmacol 579:395-402.
28. Ibrahim M, Derbyshire ER, Marletta MA, and Spiro TG (2010) Probing soluble guanylate cyclase activation by CO and YC-1 using resonance Raman spectroscopy. Biochemistry 49:3815-3823.
29. Jaiswal BS and Conti M (2003) Calcium regulation of the soluble adenylyl cyclase expressed in mammalian spermatozoa. Proc Natl Acad Sci USA 100:10676-10681. (Pubitemid 37140087)
30. Johnson RA, Désaubry L, Bianchi G, Shoshani I, Lyons E Jr, Taussig R, Watson PA, Cali JJ, Krupinski J, Pieroni JP, et al. (1997) Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3′-polyphosphates. J Biol Chem 272:8962-8966.
31. Ko FN, Wu CC, Kuo SC, Lee FY, and Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226-4233.
32. Koglin M and Behrends S (2003) A functional domain of the alpha1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding. J Biol Chem 278:12590-12597. (Pubitemid 36800249)
33. Litvin TN, Kamenetsky M, Zarifyan A, Buck J, and Levin LR (2003) Kinetic properties of "soluble" adenylyl cyclase. Synergism between calcium and bicarbonate. J Biol Chem 278:15922-15926. (Pubitemid 36799709)
34. Mülsch A, Bauersachs J, Schäfer A, Stasch JP, Kast R, and Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689. (Pubitemid 27089418)
35. Olesen SP, Drejer J, Axelsson O, Moldt P, Bang L, Nielsen-Kudsk JE, Busse R, and Mülsch A (1998) Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol 123:299-309. (Pubitemid 28039557)
36. Park WS, Ko JH, Ko EA, Son YK, Hong da H, Jung ID, Park YM, Choi TH, Kim N, and Han J (2010) The guanylyl cyclase activator YC-1 directly inhibits the voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. J Pharmacol Sci 112:64-72.
37. Ramos LS, Zippin JH, Kamenetsky M, Buck J, and Levin LR (2008) Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. J Gen Physiol 132:329-338.
38. Russwurm M, Mergia E, Mullershausen F, and Koesling D (2002) Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem 277:24883-24888. (Pubitemid 34951789)
39. Rutter GA (2001) Nutrient-secretion coupling in the pancreatic islet beta-cell: recent advances. Mol Aspects Med 22:247-284.
40. Rutter GA, Theler JM, Murgia M, Wollheim CB, Pozzan T, and Rizzuto R (1993) Stimulated Ca2+ influx raises mitochondrial free Ca2+ to supramicromolar levels in a pancreatic beta-cell line. Possible role in glucose and agonist-induced insulin secretion. J Biol Chem 268:22385-22390. (Pubitemid 23318284)
41. Soderling SH, Bayuga SJ, and Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95:8991-8996. (Pubitemid 28350602)
42. Soderling SH and Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179. (Pubitemid 30142563)
43. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, and Straub A (2002) Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Brit J Pharmacol 135:333-343. (Pubitemid 34151165)
44. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212-215. (Pubitemid 32216593)
45. Stessin AM, Zippin JH, Kamenetsky M, Hess KC, Buck J, and Levin LR (2006) Soluble adenylyl cyclase mediates nerve growth factor-induced activation of Rap1. J Biol Chem 281:17253-17258.
46. Teng CM, Wu CC, Ko FN, Lee FY, and Kuo SC (1997) YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 320:161-166.
47. Tian G, Sandler S, Gylfe E, and Tengholm A (2011) Glucose- and hormone-induced cAMP oscillations in α- and β-cells within intact pancreatic islets. Diabetes 60:1535-1543.
48. Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, and Wiemer G (1999) Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol 128:1316-1322.
49. Wu CC, Ko FN, Kuo SC, Lee FY, and Teng CM (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116:1973-1978.
50. Wu KY, Zippin JH, Huron DR, Kamenetsky M, Hengst U, Buck J, Levin LR, and Jaffrey SR (2006) Soluble adenylyl cyclase is required for netrin-1 signaling in nerve growth cones. Nat Neurosci 9:1257-1264. (Pubitemid 44454267)